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occurrence of a surgical site infection (SSI) examined by wound
closure method. Post-CABG SSIs were identiﬁed by ICD-9,
DRG, and APR-DRG codes during the initial hospital admis-
sion and re-admissions within 2 months of the initial hospital-
ization, as well as exposure to antimicrobial drugs from post-
operative day 9 to 60 during the initial hospital admission.
RESULTS: A total of 59,006 patients qualiﬁed for the study;
38,799 sutures only, 10,262 sutures/DERMABOND, 8180
sutures/staples, and 1765 sutures/staples/DERMABOND. The
groups were similar at baseline regarding patient and disease
characteristics. The lowest rate of post-CABG SSI was found in
the sutures/DERMABOND group (4.3%, 95% CI = 3.9%–
4.7%), followed by sutures only (5.3%, 95% CI = 5.1%–
5.5%), sutures/staples (6.2%, 95% CI = 5.7%–6.8%), and
sutures/staples/DERMABOND (7.1%, 95% CI = 6.0%–8.4%).
The mean (median) hospitalization cost for all patients without
post-CABG SSI was $28,061 ($25,527), compared to $47,874
($40,062) for all CABG patients who developed SSI. CON-
CLUSIONS: The results of this study suggest that the use of
both DERMABOND Topical Skin Adhesive and sutures for
wound closure following CABG surgery reduces the rate of SSI
and improves clinical outcomes. SSI following CABG surgery
imposes a signiﬁcant economic burden in terms of additional
hospitalization costs.
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OBJECTIVES: The purpose of this study was to determine the
most frequently used clopidogrel dosing regimen in the hospital
setting for acute coronary syndrome (ACS) patients undergoing
percutaneous coronary intervention (PCI). METHODS: This
was a retrospective study using the IMS Health Acute Cardio-
vascular Analyzer. This is an ongoing physician-reported registry
dating from 2005 in Germany, France, Italy, Spain and the UK.
Data collection timeframe reported here was December 2006–
November 2007. The standard dose clopidogrel group was
deﬁned as 300 mg. Demographic and health characteristics
were compiled for the entire cohort and by country. Study data
are shown as summary (or descriptive) statistics. RESULTS:
There were 4455 ACS patients who received clopidogrel and
underwent PCI. Patient count by country was: Germany
(n = 1098), France (n = 1022), Italy (n = 864), Spain (n = 804),
UK (n = 667). Mean age was 63.7  22.9 (SD) years, 46% were
age >65; 71% were male. Common co-morbidities and risk
factors were: hypertension 66.8%, dyslipidemia 74.6%, diabetes
30.6%, prior myocardial infarction (MI) 12.9%. Medications
prior to admission were: clopidogrel 15.9%, statins 34.8%,
aspirin 61.3%. The index diagnosis was: ST-elevation MI 45.0%,
non ST-elevation MI 33.1% and unstable angina 21.9%. Timing
of clopidogrel administration in relation to PCI was: 59.3%
pre-PCI, 11.8% at PCI and 17.0% after PCI (11.9% not speci-
ﬁed). Loading dose ranged from 75–900 mg. Dosage 300 mg
by country was: Germany 47.9%, France 67.8%, Italy 90.8%,
Spain 85.6%, UK 60.7%. Approximately 95% of patients were
discharged on clopidogrel but planned duration varied widely:
1–3 months (25.7%), 6–12 months (19.7%) are greater than or
equal to 12 months (26.5%). CONCLUSIONS: These 2007 data
indicate many patients received clopidogrel prior to PCI at the
300 mg dose but there was geographic variation. The vast
majority of patients received clopidogrel upon discharge, but the
planned duration of therapy varied widely. These data conti-
nue to be useful benchmarks for later comparison to treatment
guidelines.
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OBJECTIVES: To analyze the risk and costs of the ﬁrst
hypertension-associated event, compliance and persistence in
naïve hypertensive patients after initiating monotherapy with any
of the ﬁrst-line antihypertensive drug classes in Germany.
METHODS: A retrospective cohort study in the IMS Disease
Analyzer database was performed. Study subjects included all
previously untreated hypertensive adults who were free from
hypertension-associated comorbidities and were prescribed
initial monotherapy with angiotensin II receptor blockers
(ARBs), ACE-inhibitors (ACEIs), beta-blockers (BBs), calcium
channel blockers (CCBs) or diuretics. Compliance and persis-
tence were determined for each drug class separately and for the
group of non-ARBs (pooled data) within two years. The risk of
the ﬁrst hypertension-associated event (cardiovascular complica-
tions, new onset diabetes) was analyzed using a Cox regression
model adjusted for sociodemographic variables, compliance and
persistence. Based on these results average costs per event were
estimated from the German statutory health insurance perspec-
tive. RESULTS: A total of 7661 patients were identiﬁed with a
follow-up of at least 2 years. Mean follow-up was 5.6 to 6.3
years. Compliance (0.86 vs. 0.82 and 0.74, respectively) and
persistence (509 days vs. 459 and 324 days) was better with
ARBs (all p < 0.05) than with the group of non-ARBs and diuret-
ics, respectively. The risk of the ﬁrst hypertension-associated
event was higher (all p < 0.05) with diuretics (adjusted hazard
ratio (aHR) 0.68), BBs (0.79), CCBs (0.78), and the group of
non-ARBs (0.81) and was similar with ACEIs (aHR 0.93,
p = 0.37) compared to ARBs. Similar ﬁndings were found for
cardiovascular complication rates. The estimated average costs
per event for the ﬁrst event were lower with ARBs (€2339.95)
than with the other drug classes (€2531.68–€3910.47). CON-
CLUSIONS: Our real-world data indicate that initiating mono-
therapy with ARB shows signiﬁcant beneﬁts in most outcomes
including hypertension-related complications compared to other
antihypertensive drug monotherapies.
PCV109
PRESCRIPTION DRUG INSURANCE AND EX ANTE
MORAL HAZARD
Khan N1, Kaestner R2
1University of New Mexico, Albuquerque, NM, USA, 2University of
Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: Economic theory suggests that health insurance
will reduce prevention activities (i.e., ex ante moral hazard). For
instance, prescription drug insurance could result in behavioral
responses that undermine the beneﬁts of increased access to
medication. In this paper, we investigate the relationship between
prescription drug insurance and preventive health behaviors
(physical activity, alcohol consumption, smoking behavior, and
weight) among elderly population. Further, we identify two sub-
groups particularly at risk of substituting prescription drugs for
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behavior: diabetics and those with hypertension. METHODS:
Analyses are based on a nationally representative sample from
the Medicare Current Beneﬁciary Survey (MCBS) for the years
2000–2005. MCBS is a longitudinal survey and provide detailed
information on prescription drug coverage, exercise, weight, diet,
alcohol consumption, and smoking behavior. The analysis is
restricted to non-institutionalized persons above 64 years of age
with at least 2 years of data. We pay particular attention to the
non-random nature of prescription drug coverage and the selec-
tion bias caused by it. Speciﬁcally, estimates are obtained using
longitudinal data and multivariable regression models that
control for observed characteristics and unmeasured person-
speciﬁc effects (i.e., ﬁxed effects). RESULTS: An average of 16%
of the elderly switched coverage in any two consecutive years,
providing sufﬁcient variation in prescription drug coverage to
conduct ﬁxed effects analysis. In general, we ﬁnd limited evidence
of prescription drug coverage affecting health behaviors. The
lone exception was for those in public programs, where one
speciﬁcation reﬂected that elderly in the public programs were 13
percentage points (30%) less likely to participate in physical
activity than those with no prescription drug coverage after
controlling for health status. CONCLUSIONS: Although, we did
not ﬁnd any evidence of ex ante moral hazard with employer-
sponsored and HMO coverage, those in public program altered
their behavior signiﬁcantly upon gaining prescription drug
coverage.
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OBJECTIVES: The experience of TIA patients in the UK NHS
can be quite disparate. Patients presenting to primary care are
often referred to a weekly clinic, creating a delay in access to
effective treatments for this condition. The recent EXPRESS
study by Rothwell et al. (Rothwell, Peter M., et al. Lancet.
Online 9 Oct 2007 DOI:10.1016/S0140-6736(07)61448-2)
clearly demonstrated that a greater focus on effectively managing
TIA could have a signiﬁcant impact on subsequent stroke rates.
We wanted to examine how the implementation of the care
pathway outlined in Phase 2 of the EXPRESS study could affect
rates of stroke, and to explore the ﬁnancial implications of such
a shift in care. METHODS: We developed an economic model to
estimate the costs and savings associated with setting up a rapid
assessment and treatment clinic for patients with suspected TIA,
in line with Phase 2 of the EXPRESS study. We used a local
population of 500,000 people with an assumed annual incidence
of TIA of 0.19%. Current management was based on national
clinical guidelines and common clinical practice. We included all
direct costs associated with care (medications, diagnostics and
staff), and modeled the impact of changing management over a
three-year time horizon, in line with NHS planning timeframes.
RESULTS: For an assumed population of 500,000, changing the
pathway of care for TIA management resulted in 295 future
stroke events avoided over three years. As a result, the additional
costs associated with changing the pathway of care for TIA were
greatly outweighed by the savings generated through avoiding
acute management costs associated with stroke. CONCLU-
SIONS: The model suggests that the implementation of the
changes outlined in phase 2 of the EXPRESS study is cost saving
for a local population of 500,000 with an assumed TIA rate of
0.19%.
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OBJECTIVES: The aim of this study was to collect comparable
and reliable data on the lipid lowering therapy in Slovakia during
the period 1996–2006. The special interest was paid to the trend
of the statin and ﬁbrate usages. METHODS: Data of wholesalers
(following ATC/DDD), who are legally obliged to provide this
information to the Slovak Institute for Drug Control, was used
for the analysis. The results were expressed in the numbers of the
packages, ﬁnance units (€) and deﬁned daily doses per 1000
inhabitants per day (DID). RESULTS: The collected data showed
large increases in hypolipidemic consumption from 1996 to 2006
in term of DID (in 1996 (4.18), in 2001 (16.64), in 2006 (48.80).
A signiﬁcant increase in statin consumption (in 1996 (1.97), in
2001 (9.76) and in 2006 (39.66) and slight increase in ﬁbrate
consumption (in 1996 (3.59), in 2001 (6.76) and in 2006 (7.84)
in term of DID can be seen from this analysis. From the reim-
bursement point of view, simvastatin (in 2000 was reimbursed at
the level of €0.84 per DDD, in 2006 the reimbursement level was
at €0.14), ﬂuvastatin (in 2000 was reimbursed at the level of
€0.75 per DDD, in 2006 the reimbursement level was at €0.46),
atorvastatin (in 2000 was reimbursed at the level of €0.89 per
DDD, in 2006 the reimbursement level was at €0.22). Financial
expenditures were for statins (in 1996 (€989,000), in 2001
(€17,636,000) and in 2006 (€15,458,000) and for ﬁbrates
(in 1996 (€2,743,000), in 2001 (€5,570,000) and in 2006
(€3,517,000). CONCLUSIONS: Usage of generic drugs for the
treatment of hypercholesterolemia brought about a dramatic
increase in hypolipidemic consumption and the ﬁnancial expen-
ditures for health insurance funds have remained under control.
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OBJECTIVES:Assess the usage of statins in hospital after an acute
ischemic event and identify differences across Europe.
METHODS: Consecutive patients diagnosed for Ischemic Stroke
were analyzed in 2006 and 2007 in Germany, France, Italy, Spain
and UK using the Stroke Analyzer database. This was a retrospec-
tive study. RESULTS: A total of 4930 Ischemic Stroke cases were
enrolled from July 2006 until July 2007. Data were reported from
around 300 stroke specialists, neurologists, general medicine spe-
cialists. The most common treatments administered in hospital
were: aspirin 73%, statins 55%, LMWH 48%, ACE inhibitors
46%, beta blockers 21%, clopidogrel 18%. The majority of the
2726 patients treated with statins in hospital received simvastatin
47%, atorvastatin 40% and pravastatin 8%. The most common
simvastatin ﬁrst doses used were: 40 mg (48%) and 20 mg (42%).
The atorvastatin starting doses administered were mainly 20 mg
(34%), 40 mg (27%) and 80 mg (16%) atorvastatin (Spain were
leading with 25% of atorvastatin patients receiving a start dose of
80 mg). A total of 1023 patients (21%) were already receiving a
long term treatment with a statin prior to hospital admission.
Despite the fact that 56% of all ischemic stroke patients did not
have dyslipidemia, 11%of themwere already on statins before the
stroke event. Almost 31% of patients already had a previous
stroke or TIA event and 13% had a myocardial infarction more
than 1 month before the current ischemic stroke event. Treatment
with a statinwas initiated on the same day of admission to hospital
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